Form 4: Immunome CBO Granted Significant Stock Options

Immunome Inc.'s Chief Business Officer, Kinney Horn, was granted 161,000 employee stock options with an exercise price of $10.60, vesting over time.

Summary

• Kinney Horn, Chief Business Officer of Immunome Inc., was granted 161,000 employee stock options.
• The options have an exercise price of $10.60 per share.
• The grant date for these options was July 29, 2025.
• The options expire on July 28, 2035.
• The vesting schedule dictates that 25% of the shares subject to the options vest on July 29, 2026, with one-thirty-sixth (1/36th) of the remaining shares vesting every month thereafter.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of management alignment and retention strategy, though it's a routine compensation event rather than a direct operational or financial performance indicator.

Positives

• The grant of 161,000 stock options aligns the Chief Business Officer's incentives with shareholder value.
• The options have a long expiration date of July 28, 2035, providing a long-term incentive for the executive.

Future Outlook

The vesting schedule for the options, extending beyond July 2026 with monthly vesting thereafter, indicates a long-term incentive structure for the Chief Business Officer, aligning future performance with equity value.

Industry Context

The grant of stock options to a Chief Business Officer is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Granting stock options to senior executives like a Chief Business Officer is a standard compensation practice across the biotech and pharmaceutical sectors, comparable to similar incentive structures seen at companies such as Moderna, BioNTech, or Regeneron, which often use equity-based awards to motivate leadership.
• The vesting schedule, with an initial cliff followed by monthly vesting, is a common design for long-term incentive plans in the industry, promoting executive retention and sustained performance over several years.

Related Party Transactions

• Grant of 161,000 employee stock options to Kinney Horn, the Chief Business Officer, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal a stable and incentivized leadership team, potentially boosting morale and confidence.

Next Steps

• Continued vesting of the granted stock options according to the specified schedule.

Key Dates

Recommendation

This Form 4 reports a routine grant of employee stock options to a key executive, which is a standard compensation practice aimed at aligning management incentives with shareholder interests. It does not contain information that would fundamentally alter the investment thesis for Immunome Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Immunome, IMNM, stock options, insider transaction, Form 4, executive compensation, Kinney Horn, Chief Business Officer